Riley J. Regimbal

TL;DR: Early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and given the deadly nature of COVID 19 and the large population of critically-ill patients, the mortality rate does not appear excessive.

TL;DR: In this paper, the anti-SARS-CoV-2 antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19 were determined based on a U.S. national registry, and the primary outcome was death within 30 days after plasma transfusion.

TL;DR: New data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of CO VID-19 is more likely to reduce mortality.

TL;DR: The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels provide signatures of efficacy for convalescent plasma in the treatment of hospitalized COVID-19 patients.

TL;DR: In this paper, a meta-analysis of randomized, crossover, placebo-controlled studies reporting exercise performance outcome metrics with NO3 supplementation in young, healthy adults was conducted, showing that the effect size of NO3 supplements was objectively small (d = 0.174; 95% confidence interval (CI), 0.120-0.229; P < 0.001).